Valuation: Penumbra, Inc.

Market Cap 12.87B 11.04B 10.31B 9.46B 17.79B 1,231B 18.08B 122B 47.65B 617B 48.34B 47.29B 2,040B P/E 2026 *
74.1x
P/E 2027 * 53.4x
Enterprise Value 12.43B 10.66B 9.95B 9.13B 17.17B 1,188B 17.46B 117B 45.99B 596B 46.66B 45.65B 1,970B EV / Sales 2026 *
7.8x
EV / Sales 2027 * 6.75x
Free-Float
97.11%
Yield 2026 *
-
Yield 2027 * -
1 day+0.64%
1 week+0.08%
Current month+1.76%
1 month+2.68%
3 months+0.09%
6 months-4.06%
Current year+5.12%
1 week 324.75
Extreme 324.75
328.6
1 month 315.7
Extreme 315.7
328.6
Current year 290
Extreme 290
362.41
1 year 221.26
Extreme 221.26
362.41
3 years 148
Extreme 148
362.41
5 years 114.86
Extreme 114.865
362.41
10 years 56.05
Extreme 56.05
362.41
Manager TitleAgeSince
Chief Executive Officer 64 2004-06-20
President 41 2025-08-31
Director of Finance/CFO 54 2019-12-01
Director TitleAgeSince
Chairman 64 2014-12-31
Chairman 64 2004-12-31
Director/Board Member 59 2015-03-31
Date Insider Type Main position Quantity % Market Cap.
2/13/26 Free

Founder

589 0.0015%
2/13/26 Free

Director

589 0.0015%
2/13/26 Free

General Counsel

5,742 0.0146%
Change 5-day change 1-year change 3-year change Capi.($)
+0.64%+0.08%+29.08%+30.10% 12.79B
+1.45%+2.01%+18.38%+33.61% 6.87B
+2.64%+4.14%+55.05%+48.90% 6.82B
+4.44%-2.32% - - 5.44B
+1.73%+5.78%-20.33%+62.13% 4.7B
-0.54%-4.11%-28.09%-23.16% 3.85B
+5.57%+3.47%+50.79%-41.38% 2.01B
-0.49%-8.07%+46.43%-9.69% 1.66B
-2.73%+1.33%-34.03%+121.99% 1.63B
-2.20%-3.68%-31.08%-43.94% 1.31B
Average +1.04%+0.38%+9.58%+19.84% 4.71B
Weighted average by Cap. +1.46%+0.82%+18.07%+28.69%

Financials

2026 *2027 *
Net sales 1.59B 1.37B 1.28B 1.17B 2.2B 152B 2.24B 15.06B 5.9B 76.36B 5.98B 5.85B 252B 1.8B 1.54B 1.44B 1.32B 2.49B 172B 2.53B 17.01B 6.66B 86.28B 6.76B 6.61B 285B
Net income 176M 151M 141M 130M 244M 16.86B 248M 1.67B 653M 8.46B 662M 648M 27.96B 242M 208M 194M 178M 335M 23.16B 340M 2.29B 897M 11.62B 910M 890M 38.41B
Net Debt -447M -383M -358M -328M -618M -42.72B -628M -4.22B -1.65B -21.43B -1.68B -1.64B -70.85B -729M -625M -584M -535M -1.01B -69.65B -1.02B -6.89B -2.7B -34.93B -2.74B -2.68B -115B
Logo Penumbra, Inc.
Penumbra, Inc. is a thrombectomy company, which is focused on developing technologies for challenging medical conditions, such as ischemic stroke, venous thromboembolism, such as pulmonary embolism, and acute limb ischemia. The Company's broad portfolio, which includes computer assisted vacuum thrombectomy (CAVT), centers on removing blood clots from head-to-toe. It focuses on developing, manufacturing and marketing novel products for use by specialist physicians and healthcare providers to drive improved clinical and health outcomes. Some of the conditions it focuses on are Pulmonary Embolism, Deep Vein Thrombosis, Acute Limb Ischemia, Ischemic Stroke, Acute Coronary Syndrome, and Clot associated with Arteriovenous Graft or Fistula. The Company sells its products to healthcare providers primarily through its direct sales organization in the United States, Europe, Canada, Australia and Singapore, as well as through distributors in select international markets.
Employees
4,700
Date Price Change Volume
26-08-19 US$326.84 +0.64% 305,254
26-08-18 US$324.75 -0.74% 176,790
26-08-17 US$327.17 +0.05% 187,634
26-08-14 US$327.02 +0.08% 251,610
26-08-13 US$326.75 +0.05% 209,553
Trader
Investor
Global
Quality
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
16
Last Close Price
326.84USD
Average target price
361.83USD
Spread / Average Target
+10.71%

Quarterly revenue - Rate of surprise